Treat to target in axial spondyloarthritis: From its concept to its implementation

•A better knowledge of the natural history of spondyloarthritis permits to select surrogate markers of long term disability.

•Abrogation of inflammation should be the main target in axial spondyloarthritis.

•Other targets can be considered (e.g. NSAID intake reduction, treatment of predisposing factors to cardiovascular diseases).

•Novel therapies (e.g. TNF blockers, IL17 inhibitiors) are facilitating a teat to target approach.

•Implementation of a treat to target approach in spondyloarthritis should be further investigated.

https://doi.org/10.1016/j.jaut.2019.102398

MaximeDougados

Université de Paris, Department of Rheumatology – Hôpital Cochin, Assistance Publique – Hôpitaux de Paris, INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France